Publicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (20)

2024

  1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

    Frontiers in Immunology, Vol. 15

2023

  1. Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

    ESMO Open, Vol. 8, Núm. 4

2021

  1. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab

    Molecular Oncology, Vol. 15, Núm. 11, pp. 2923-2940

  2. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  3. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers

    Clinical and Experimental Metastasis, Vol. 38, Núm. 2, pp. 239-251

2020

  1. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

    Journal of Chemotherapy, pp. 1-13

  2. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

    World Journal of Gastroenterology, Vol. 26, Núm. 13, pp. 1513-1524

  3. Global gene expression characterization of circulating tumor cells in metastasic castration-resistant prostate cancer patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-14

2017

  1. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients

    Oncotarget, Vol. 8, Núm. 33, pp. 54708-54721

2016

  1. Clinical application of circulating tumour cells in prostate cancer: From bench to bedside and back

    International Journal of Molecular Sciences, Vol. 17, Núm. 9

  2. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

    Current Oncology Reports, Vol. 18, Núm. 12

2014

  1. Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment

    Cancers, Vol. 6, Núm. 1, pp. 153-165

2013

  1. Zoledronic acid in genitourinary cancer

    Clinical and Translational Oncology, Vol. 15, Núm. 11, pp. 871-878

2012

  1. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

    Journal of Cellular and Molecular Medicine, Vol. 16, Núm. 10, pp. 2342-2349

  2. Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: Results of a pilot study

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 688-694

  3. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 1, pp. 138-144

2011

  1. Adenocarcinoma de ciego en paciente con

    Gastroenterologia y Hepatologia

  2. High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion

    Molecular Cancer Therapeutics, Vol. 10, Núm. 8, pp. 1357-1366

2010

  1. Cáncer de ovario. Enfermedad platino resistente

    Revisiones en Cancer, Vol. 24, Núm. 6, pp. 253-262

2008

  1. Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome

    Arquivos Brasileiros de Endocrinologia e Metabologia, Vol. 52, Núm. 6, pp. 1066-1070